KA
DGX icon

Kozak & Associates’s Quest Diagnostics DGX Stock Holding History

Kozak & Associates’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1
Closed -$154 – 445
2024
Q3 		$154 Hold
1
– – ﹤0.01% 373
2024
Q2 		$145 Hold
1
– – ﹤0.01% 371
2024
Q1 		$147 Buy
+1
New +$130 ﹤0.01% 376

Other funds holding DGX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
DSA
Davis Selected Advisers Tucson, Arizona $21.8B AUM 23.45% 1-Year Est. Return
Grantham, Mayo, Van Otterloo & Co (GMO)
Grantham, Mayo, Van Otterloo & Co (GMO) Boston, Massachusetts $39.1B AUM 28.69% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Kozak & Associates's DGX Position: Q4 2024 in Review

Kozak & Associates sold out of Quest Diagnostics (DGX) in Q4 2024, closing a stake of 1 share — an estimated $154 sold.

Kozak & Associates first reported a position in DGX in Q1 2024 and held it in 3 quarters. The position peaked at $154 in Q3 2024. 895 funds tracked by Wall St. Rank hold DGX as of Q4 2024.

  • Kozak & Associates reported no remaining Quest Diagnostics position as of Q4 2024 after selling out during the quarter.
  • Kozak & Associates sold 1 Quest Diagnostics share in Q4 2024, an estimated $154.
  • Kozak & Associates first reported a position in Quest Diagnostics in Q1 2024 and held it in 3 quarters.
  • Kozak & Associates's Quest Diagnostics position peaked at $154 in Q3 2024.
  • 895 funds tracked by Wall St. Rank held Quest Diagnostics as of Q4 2024.

Based on Kozak & Associates's 13F filing for Q4 2024, filed 6 Jan 2025.